Literature DB >> 1379194

Characterization of human umbilical vein endothelial cell lines produced by transfection with the early region of SV40.

S A Fickling1, J A Tooze, G S Whitley.   

Abstract

Human umbilical vein endothelial cells were transfected by electroporation with the plasmid pSV3neo, containing the early region of simian virus 40. The resultant "cell lines" divide rapidly (population doubling time of 33 h) for up to 24 passages in medium supplemented with 5% (v/v) serum and 2.5 micrograms/ml endothelial cell growth supplement. Several of these lines express basal levels of ICAM-1 and MHC class I but not MHC class II. One cell line, designated SGHEC-7, retained a number of differentiated endothelial cell functions throughout its lifespan. These functions include increased production of tissue plasminogen activator in response to histamine, thrombin, and PMA. Stability of function and rapid growth over 24 passages endow these cells with a number of advantages over primary cultures. The homogeneous cell population and consistency of response make them ideal for biochemical and immunological studies hereto impractical with primary human endothelial cells. The success of this approach may allow the production of functional cell lines from other vascular beds.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1379194     DOI: 10.1016/0014-4827(92)90303-p

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  11 in total

1.  Characterization of novel clonal murine endothelial cell lines with an extended life span.

Authors:  U Cavallaro; V Castelli; A Perilli; R Dossi; R Giavazzi; M S Pepper; M R Soria; R Montesano
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-05       Impact factor: 2.416

2.  Immortalized glomerular endothelial cells transfected.

Authors:  K Nitta
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-01       Impact factor: 2.416

3.  Production of immortal human endothelial cell lines by strontium phosphate transfection and electroporation of SV40 sequences.

Authors:  U Fitzgerald; J S McLean; C MacDonald
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-04       Impact factor: 2.416

4.  Umbilical cord endothelial cells expressing large T antigen: comparison with primary cultures and effect of cell age.

Authors:  U Fitzgerald; S Hettle; C MacDonald; J S McLean
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-04       Impact factor: 2.416

5.  Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase.

Authors:  R J MacAllister; H Parry; M Kimoto; T Ogawa; R J Russell; H Hodson; G S Whitley; P Vallance
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

6.  Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers.

Authors:  C P Denton; X Shi-Wen; A Sutton; D J Abraham; C M Black; J D Pearson
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

7.  Metabolism of methylarginines by human vasculature; implications for the regulation of nitric oxide synthesis.

Authors:  R J MacAllister; S A Fickling; G S Whitley; P Vallance
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

8.  Impaired decidual natural killer cell regulation of vascular remodelling in early human pregnancies with high uterine artery resistance.

Authors:  Rupsha Fraser; Guy Stj Whitley; Alan P Johnstone; Amanda J Host; Neil J Sebire; Baskaran Thilaganathan; Judith E Cartwright
Journal:  J Pathol       Date:  2012-07-18       Impact factor: 7.996

9.  Decidual natural killer cells regulate vessel stability: implications for impaired spiral artery remodelling.

Authors:  Rupsha Fraser; Guy St J Whitley; Baskaran Thilaganathan; Judith E Cartwright
Journal:  J Reprod Immunol       Date:  2015-05-12       Impact factor: 4.054

10.  Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis.

Authors:  V Kostourou; S P Robinson; J E Cartwright; G St J Whitley
Journal:  Br J Cancer       Date:  2002-09-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.